Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)

The Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access program is administered by the National Institutes of Health (NIH), an agency within the U.S. Department of Health and Human Services, with oversight by the National Human Genome Research Institute. CIDR functions as a centralized national resource that provides high-throughput genotyping and sequencing services to support biomedical research. The initiative is designed to enable investigators to access advanced genomic technologies and statistical genetics expertise that may not be feasible to conduct independently within individual laboratories. By centralizing these capabilities, the program aims to accelerate discoveries related to genetic contributions to human health and disease. The primary purpose of this opportunity is to support research projects that seek to identify genes or genetic variants associated with diseases or health conditions, or to enhance the classification and characterization of biological specimens through the addition of genomic data. CIDR offers access to cutting-edge sequencing platforms and analytical support, allowing researchers to generate high-quality genomic datasets. These services are intended to complement existing research efforts by providing specialized resources rather than direct monetary awards, making this mechanism distinct from traditional grant funding programs. Funding under this opportunity is provided as a resource access mechanism rather than direct financial assistance. As such, applicants do not receive funds directly but instead gain access to CIDR’s laboratory services, including sequencing, genotyping, and statistical genetics support. The program emphasizes efficient use of centralized infrastructure to maximize research output and cost-effectiveness. There are no stated cost-sharing or matching requirements, and allowable uses are limited to the scope of services provided through CIDR facilities and personnel. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of organizational types. Eligible applicants include institutions of higher education (both public and private), nonprofit organizations with or without 501(c)(3) status, small and large businesses, government entities at the state, local, and tribal levels, independent school districts, and public housing authorities. Additional eligible entities include federal agencies, U.S. territories, faith-based organizations, regional organizations, and non-U.S. institutions. This wide eligibility scope reflects NIH’s goal of supporting diverse research collaborations across sectors and geographic regions. The application process is expected to follow NIH submission protocols, though specific application components are not detailed in the forecast notice. Applicants will likely be required to submit research proposals outlining study design, objectives, and justification for using CIDR services. Proposals are typically evaluated based on scientific merit, feasibility, and alignment with program goals. As this is a forecasted opportunity, applicants are encouraged to monitor updates and prepare materials in advance of the official posting. The timeline for this opportunity indicates an estimated posting date of August 10, 2026, with an anticipated application due date of September 3, 2026. Awards are expected to be issued by December 4, 2026, with project start dates aligned to the same timeframe. This suggests a relatively short application window and rapid turnaround for funding decisions. Interested applicants should prepare early and ensure compliance with NIH submission systems and requirements. For additional information or inquiries, applicants are directed to contact the CIDR team via email at nhgri-research-funding@nih.gov. Further details about available services and program capabilities can be accessed through the CIDR website. As an NIH-wide initiative, this program represents a significant opportunity for researchers seeking access to advanced genomic technologies and collaborative scientific support.